At the time of writing, Mirum Pharmaceuticals Inc [MIRM] stock is trading at $96.03, up 2.96%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The MIRM shares have gain 5.93% over the last week, with a monthly amount glided 23.53%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Mirum Pharmaceuticals Inc [NASDAQ: MIRM] stock has seen the most recent analyst activity on September 24, 2025, when TD Cowen initiated its Buy rating and assigned the stock a price target of $95. Stifel started tracking the stock assigning a Buy rating and suggested a price target of $48 on April 17, 2024. H.C. Wainwright reiterated its recommendation of a Buy and reduced its price target to $58 on December 18, 2023. In a note dated November 13, 2023, Morgan Stanley initiated an Overweight rating and provided a target price of $60 on this stock.
For the past year, the stock price of Mirum Pharmaceuticals Inc fluctuated between $36.88 and $93.99. Currently, Wall Street analysts expect the stock to reach $105.7 within the next 12 months. Mirum Pharmaceuticals Inc [NASDAQ: MIRM] shares were valued at $96.03 at the most recent close of the market. An investor can expect a potential return of 10.07% based on the average MIRM price forecast.
Analyzing the MIRM fundamentals
According to Mirum Pharmaceuticals Inc [NASDAQ:MIRM], the company’s sales were 471.79M for trailing twelve months, which represents an 47.17% jump. Gross Profit Margin for this corporation currently stands at 0.8% with Operating Profit Margin at -0.09%, Pretax Profit Margin comes in at -0.09%, and Net Profit Margin reading is -0.09%. To continue investigating profitability, this company’s Return on Assets is posted at -0.05, Equity is -0.16 and Total Capital is -0.07. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 1.09.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It is important to note that Mirum Pharmaceuticals Inc [NASDAQ:MIRM] has a current ratio of 3.31. In addition, the Quick Ratio stands at 3.16 and the Cash Ratio stands at 1.76. Considering the valuation of this stock, the price to sales ratio is 10.52, the price to book ratio is 16.87.
Transactions by insiders
Recent insider trading involved Quan Joanne, CHIEF MEDICAL OFFICER, that happened on Jan 20 ’26 when 6911.0 shares were sold. Director, Ramasastry Saira completed a deal on Jan 15 ’26 to sell 2000.0 shares. Meanwhile, Director SAIRA RAMASASTRY bought 2000.0 shares on Jan 15 ’26.
